NCT06896994View on ClinicalTrials.gov

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

May 1, 2026

Conditions
Postherpetic Neuralgia
Interventions
DRUG

esketamine group

In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.

DRUG

control group

receiving the combination of pregabalin and duloxetine

Trial Locations (1)

100070

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Xiaotangshan Hospital

OTHER

collaborator

The First Hospital of Fangshan District,Beijing

OTHER

collaborator

Beijing Ditan Hospital

OTHER

collaborator

Hengshui People's Hospital

OTHER

lead

Beijing Tiantan Hospital

OTHER